BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

N/A
indicator

Bse Healthcare

1D
1M
3M
6M
1Y
5Y
empty graph

Bse Healthcare Performance

Day's Range

Low

₹47,252.15

High

₹47,888.68

52 Week Range

Low

₹40,239.45

High

₹48,086.59

Previous Close ₹47,337.55
Day's Range ₹47,252.15 - ₹47,888.68
Open ₹47,888.68
52 Week Range ₹40,239.45 - ₹48,086.59
Volume 20,32,097

Bse Healthcare Companies

Company Name LTP (₹) Change (₹) Sector
Cipla Ltd. 1377.20 Arrow -11.60 (-0.84%) Healthcare
Dr. Reddy's Laboratories Ltd. 1285.00 Arrow 11.10 (0.87%) Healthcare
Procter & Gamble Health Ltd. 6262.00 Arrow -11.55 (-0.18%) Healthcare
Lupin Ltd. 2280.40 Arrow -12.30 (-0.54%) Healthcare
Morepen Laboratories Ltd. 50.38 Arrow 0.22 (0.44%) Healthcare
Torrent Pharmaceuticals Ltd. 4529.85 Arrow -45.10 (-0.99%) Healthcare
Abbott India Ltd. 26350.00 Arrow 77.95 (0.30%) Healthcare
Glaxosmithkline Pharmaceuticals Ltd. 2152.10 Arrow 31.40 (1.48%) Healthcare
Novartis India Ltd. 1298.60 Arrow -5.25 (-0.40%) Trading
Sanofi India Ltd. 3272.30 Arrow 152.35 (4.88%) Healthcare

All Indices

Index Name Market Value 52W High 52W Low
Nifty 50 23941.65 26373.20 22182.55
Nifty IT 28022.7 40301.40 27078.00
Nifty Next 50 71718.9 72442.15 59896.10
NIFTY50 USD Index 8774.1 10443.40 8132.40
Nifty Bank 57399.95 61764.85 49954.85
NIFTY Midcap 100 61635.05 62907.50 52032.85
Nifty 500 22953.7 24144.20 20385.65
Nifty Midcap 50 17513.4 17859.10 14804.55
Nifty 100 24984.6 26975.15 22720.45
Nifty FMCG 49125.05 58485.05 45334.15

Latest News

Jun
12
2026
EQUITY Posted on Jun 12th 2026

AstraZeneca Pharma India informs about resignation of senior management personnels

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), AstraZeneca Pharma India has informed that Aditi Mehta, Business Unit Director - Oncology Business Unit, of the Company has decided to pursue a career outside the organization. Mehta will complete her handover period and be relieved from duties by the close of business hours on June 12, 2026. The Company is in the process of looking for a suitable replacement for this position; Srikanth B.S., Site Lead, India Operations has decided to pursue a career outside the organization. Srikanth will complete his handover period and be relieved from duties by the close of business hours on June 15, 2026. These being Senior Management Personnel position in terms of the SEBI Listing Regulations, the company has enclosed details as required under the SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, attached as Annexure- A, alongwith their respective copies of the resignation letters enclosed.
The above information is a part of company’s filings submitted to BSE. 
Read More
Jun
12
2026
EQUITY Posted on Jun 12th 2026

Suven Life Sciences informs about news release

Suven Life Sciences has informed that it enclosed News Release of the company titled ‘Suven Life Sciences announces three poster presentations on Samelisant (SUVN-G3031), including global Phase-3, AWAKE Narcolepsy Study at the SLEEP-2026 Annual Meeting being held at Baltimore, USA’.

The above information is a part of company’s filings submitted to BSE. 

Read More
Jun
12
2026
EQUITY Posted on Jun 12th 2026

Unichem Laboratories informs about disclosure

Unichem Laboratories has informed that it enclosed disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Equity Intelligence India.
The above information is a part of company’s filings submitted to BSE.
Read More
Jun
12
2026
EQUITY Posted on Jun 12th 2026

Emcure Pharmaceuticals informs about investor presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, Emcure Pharmaceuticals has informed that it enclosed the ‘Investor Presentation – June 2026’. The same is also available on the Company’s website: www.emcure.com.
The above information is a part of company’s filings submitted to BSE. 
Read More
Jun
11
2026
EQUITY Posted on Jun 11th 2026

Alembic Pharmaceuticals informs about press release

Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Larotrectinib Capsules, 25 mg and 100 mg. The Company has enclosed its press release.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Frequently Asked Questions

What is the Previous Close of index?

The previous close of index is ₹ as of .

The total volume of index is as of .

The percentage change in value of index is % as of .

The absolute increase in index value since the previous trading day is ₹ as of .

A stock reaching its 52-week high indicates it has attained its highest price point in the past year. This milestone may signal strong performance and positive investor sentiment. Please note that investments are subject to market risks.

View More
Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore